Top 5 Stocks to Buy Now
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free LIPO Stock Alerts

Lipella Pharmaceuticals (LIPO) Competitors

Lipella Pharmaceuticals logo
$0.09 0.00 (0.00%)
As of 06/25/2026 12:59 PM Eastern
Compare

LIPO vs. HEPA, ATXI, CARM, PTIX, and VRAX

Should you buy Lipella Pharmaceuticals stock or one of its competitors? MarketBeat compares Lipella Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipella Pharmaceuticals include Hepion Pharmaceuticals (HEPA), Avenue Therapeutics (ATXI), Carisma Therapeutics (CARM), Atrinsic (PTIX), and Virax Biolabs Group (VRAX). These companies are all part of the "pharmaceutical products" industry.

How does Lipella Pharmaceuticals compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Lipella Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Lipella Pharmaceuticals$536.36K0.78-$5.02M-$2.42N/A

Hepion Pharmaceuticals has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Lipella Pharmaceuticals Neutral

Summary

Lipella Pharmaceuticals beats Hepion Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Avenue Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Lipella Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A
Lipella Pharmaceuticals$536.36K0.78-$5.02M-$2.42N/A

Avenue Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Avenue Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
Lipella Pharmaceuticals Neutral

Summary

Lipella Pharmaceuticals beats Avenue Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Carisma Therapeutics?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Carisma Therapeutics has a net margin of -254.28% compared to Lipella Pharmaceuticals' net margin of -988.83%. Carisma Therapeutics' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Carisma Therapeutics -254.28%N/A -192.17%

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Carisma Therapeutics Neutral

Carisma Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 12,245.68%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Lipella Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

Lipella Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.78-$5.02M-$2.42N/A
Carisma Therapeutics$10.77M0.03-$60.48M$0.730.01

Lipella Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Carisma Therapeutics beats Lipella Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Atrinsic?

Atrinsic (NASDAQ:PTIX) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Atrinsic has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Atrinsic has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Atrinsic's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A N/A -379.72%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

In the previous week, Atrinsic's average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Atrinsic Neutral
Lipella Pharmaceuticals Neutral

Lipella Pharmaceuticals has higher revenue and earnings than Atrinsic. Atrinsic is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M-$3.45N/A
Lipella Pharmaceuticals$536.36K0.78-$5.02M-$2.42N/A

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Lipella Pharmaceuticals beats Atrinsic on 8 of the 11 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Virax Biolabs Group has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

In the previous week, Virax Biolabs Group had 10 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 10 mentions for Virax Biolabs Group and 0 mentions for Lipella Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 0.36 beat Lipella Pharmaceuticals' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company Overall Sentiment
Virax Biolabs Group Neutral
Lipella Pharmaceuticals Neutral

Virax Biolabs Group has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Virax Biolabs Group's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

Virax Biolabs Group currently has a consensus target price of $1.00, indicating a potential downside of 67.85%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than Lipella Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lipella Pharmaceuticals has higher revenue and earnings than Virax Biolabs Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K1,349.74-$6.06MN/AN/A
Lipella Pharmaceuticals$536.36K0.78-$5.02M-$2.42N/A

Summary

Virax Biolabs Group beats Lipella Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Lipella Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIPO vs. The Competition

Export
MetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$416K$3.61B$6.81B$12.17B
Dividend YieldN/A2.27%2.68%5.90%
P/E Ratio-0.0221.7525.7924.20
Price / Sales0.78305.57548.6394.36
Price / CashN/A134.9146.3353.91
Price / Book0.068.3410.776.37
Net Income-$5.02M$23.91M$3.57B$337.69M
7 Day PerformanceN/A6.88%3.15%-0.30%
1 Month PerformanceN/A5.54%2.34%0.37%
1 Year PerformanceN/A62.60%33.41%26.93%

Lipella Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIPO
Lipella Pharmaceuticals
N/A$0.09
flat		N/A-89.7%$416K$536.36KN/A4
HEPA
Hepion Pharmaceuticals
N/A$0.08
+55.3%		N/A-34.1%$915KN/AN/A20
ATXI
Avenue Therapeutics
N/A$0.27
flat		N/A+27.0%$890KN/A0.014
CARM
Carisma Therapeutics
2.5285 of 5 stars		$0.02
-6.1%		$1.00
+4,900.0%		-98.0%$837K$10.77M0.0320
PTIX
Atrinsic
N/A$0.41
+1.2%		N/A-90.2%$742KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LIPO) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Elon Musk, Larry Fink & Brian Armstrong are ALL Piling into This
Elon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...
Brownstone Research | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Problems at SpaceX: time to get out?
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker included
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel